Panoramic view of Celltrion headquarters. Provided by Celltrion
Celltrion stated on the 30th that it is expanding sales of new biopharmaceuticals such as Omlyclo and Aptozma in the European market. Supported by rising market shares of major products and successful tender bids, the sales proportion of its high-margin new product portfolio is also increasing.
According to pharmaceutical market research firm IQVIA, Omlyclo (ingredient name: omalizumab), a treatment for chronic spontaneous urticaria and allergic diseases that was launched in Europe in the second half of last year, recorded a 30% market share in Europe as of the second quarter of this year. Among the major five EU countries (EU5), it secured a 47% share in the United Kingdom and 25% in Italy.
Aptozma (ingredient name: tocilizumab), a treatment for autoimmune diseases, recorded a 13% share of the European market during the same period, roughly doubling from the previous quarter. In Spain and Portugal, it achieved market shares of 32% and 66%, respectively.
Another autoimmune disease treatment, Steqima (ingredient name: ustekinumab), won major regional government tenders in Italy, including in Tuscany and Emilia-Romagna, and recorded a 28% local market share.
Existing flagship products are also maintaining high market shares in Europe. The Remsima product family (IV·SC) recorded a 70% share of the overall infliximab market in Europe and 77% in the EU5. In France, its share approached 80%.
Earlier this year, Celltrion expanded its supply portfolio by launching the Remsima IV liquid formulation. Its Dutch subsidiary signed a supply contract in the third quarter with a hospital group composed of seven local university hospitals. Under this agreement, from February 2027, the group’s entire infliximab demand will be supplied with the Remsima IV liquid formulation.
Yuflyma (ingredient name: adalimumab), an autoimmune disease treatment, maintained the No. 1 position with a 30% share in the EU5. Vegzelma (ingredient name: bevacizumab), an anticancer drug, also retained the lead with a 34% share of the European market.
The expansion of new product sales was reflected in third-quarter earnings. Celltrion’s third-quarter revenue from new product lines was KRW 905.8 billion, accounting for 67% of its biopharmaceutical sales. Omlyclo posted cumulative sales of KRW 320.5 billion in the third quarter of this year.
Celltrion plans to increase the sales proportion of its new product portfolio to 70% by strengthening participation in country-specific tenders in Europe and enhancing promotion to medical institutions.
A Celltrion representative said, “In Europe, tender wins and prescriptions for new product lines such as Omlyclo and Aptozma are expanding,” adding, “Based on a field-focused direct sales strategy, the company will concentrate on winning major national tenders and increasing prescriptions at medical institutions.”
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
Popular News